Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Short term Debt (2018 - 2019)

Historic Short term Debt for 10x Genomics (TXG) over the last 2 years, with Q4 2019 value amounting to $9.9 million.

  • 10x Genomics' Short term Debt rose 13601.62% to $9.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $9.9 million, marking a year-over-year increase of 13601.62%. This contributed to the annual value of $9.9 million for FY2019, which is 13601.62% up from last year.
  • As of Q4 2019, 10x Genomics' Short term Debt stood at $9.9 million, which was up 13601.62% from $7.4 million recorded in Q3 2019.
  • 10x Genomics' Short term Debt's 5-year high stood at $9.9 million during Q4 2019, with a 5-year trough of $4.2 million in Q4 2018.